Mohammed Amrallah A, El-Shentenawy Ayman
Oncology Center, King Abdullah Medical City-Holy Capital, Muzdallifa Streat, P.O. Box 57657, Makkah, 21995, Saudi Arabia,
Med Oncol. 2014 Jul;31(7):49. doi: 10.1007/s12032-014-0049-x. Epub 2014 Jun 8.
Since chemotherapy has been shown to be unsuccessful in case of advanced thyroid carcinomas, the research for new therapies is fundamental. Clinical trials of many tyrosine kinase inhibitors as well as anti-angiogenic inhibitors suggest that patients with thyroid cancer could have an advantage with new target therapy. Recently, Food and Drug Administration approved two targeted therapies, vandetanib and cabozantinib for the treatment of metastatic thyroid carcinomas with acceptable outcome. We summarized the results and the toxic effects associated with these treatments reported in clinical trials. Future trials should aim at combinations of targeted agents with or without other treatment modalities to obtain a more effective result in thyroid carcinoma treatment.
由于化疗已被证明对晚期甲状腺癌无效，因此寻找新的治疗方法至关重要。许多酪氨酸激酶抑制剂以及抗血管生成抑制剂的临床试验表明，甲状腺癌患者可能从新的靶向治疗中获益。最近，美国食品药品监督管理局批准了两种靶向治疗药物凡德他尼和卡博替尼用于治疗转移性甲状腺癌，疗效尚可。我们总结了临床试验中报道的这些治疗方法的结果及相关毒性作用。未来的试验应旨在将靶向药物与其他治疗方式联合或不联合使用，以在甲状腺癌治疗中获得更有效的结果。
